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Comments Regarding Practice Recommendations
of the American Thyroid Association for Radiation Safety
in the Treatment of Thyroid Disease with Radioiodine
James V. Hennessey,1 J. Anthony Parker,2 Rosemary Kennedy,3 and Jeffrey R. Garber4
Dear Editor:
The authors of the recently published ‘‘Radiation Safety in the
Treatment of Patients with Thyroid Diseases by Radioiodine
(131I): Practice Recommendations of the American Thyroid
Association’’ (1) are to be commended for creating a docu-
ment that reflects the result of countless hours of literature
review, survey compilation, discussion, and compromise. This
study has systematically applied techniques to achieve as low
as reasonably achievable (ALARA) exposure to radiation, and
this represents a significant step forward in the protection of
those coming in contact with individuals treated with 131I. It
effectively communicates newer approaches to assessing the
likely maximum dose to another person (usually family) that
are not only based on total administered doses but also esti-
mates of clearance and retention. For example, an individual
with Graves’ disease with high radioactive iodine uptake who
received 10 millicurie (mCi) of 131I may expose others to more
radiation than someone with thyroid cancer post–total thy-
roidectomy, stimulated with rhTSH and ablated with 100 mCi.
We have already modified our institution’s protocols by
adapting some of the committee’s recommendations.
However, we would like to share our concerns about
some of the committee’s recommendations regarding the
following.
In regard to the section titled ‘‘Post-therapy living situa-
tions,’’ the recommendation about sleeping in separate beds,
the committee should consider the dynamic clearance of the
131I as predicted by the expected pharmacokinetics of 131I. For
example, the amount of radioiodine delivered to and retained
in the thyroid gland of a patient with Graves’ disease who
receives 10 mCi is often greater than the radiation exposure of
someone with a multinodular goiter who is either euthyroid
or only mildly hyperthyroid receiving 30 mCi. Yet, the former
patient would be advised to sleep alone for 3 days, while the
latter patient would be told to do so for 11 days.
The section entitled ‘‘Personal hygiene’’ contains instruc-
tions on the disposal of radioactive trash that cannot be flu-
shed or washed in a routine fashion which require several
considerations. First of all, just how much contamination will
there be? Highly conscientious, environmentally aware, in-
dependently living people are unlikely to generate much ra-
dioactive trash. On the other hand, a debilitated, dependent
patient, who wears incontinence diapers, is quite likely to
produce a significant amount of contamination. Recom-
mendations should, therefore, be based on likely levels of
contamination. For example, when considering the use of
disposable versus washable utensils, we recommend using
washable utensils—as opposed to disposable ones. We in-
struct patients to wash them separately from the family dishes
whenever possible. This minimizes the amount of material
that must be stored. When counseling patients about trans-
porting radioactive trash, the recommendation states, ‘‘Bring
your specified trash bag back to the treatment facility.’’ We
feel that it is not feasible for many urban dwellers who are
dependent on public transportation, which should not be
used for this purpose, to comply with this recommendation.
Further, in regard to the home storage of radioactive trash, it is
recommended that, ‘‘After 80 days the bag may be removed as
other trash bags.’’ We believe that holding biohazard trash for
80 days poses a hygienic risk and storage challenge for those
living in small apartments in multi-unit dwellings. Seeking
alternative storage options may force them to compromise
their right to privacy and expose others to unnecessary radi-
ation. We recommend landfill disposal after a shorter period
for continent patients, such as 4 weeks depending on the
sensitivity of local landfill detectors. Incontinent patients
should be treated as inpatients. Willegaignon et al.’s (2) ex-
perience in Brazil indicates that patient home waste contam-
ination levels were a third of the International Atomic Energy
Agency (IAEA) concentration limit for release criteria. We
propose that our professional societies request that the Nu-
clear Regulatory Commission (NRC) adopt IAEA limits as
reasonable alert levels for waste site monitors.
Driving an automobile while potentially impaired by the
effects of hypothyroidism has led us to carefully consider our
recommendations to patients undergoing thyroid hormone
withdrawal procedures. We routinely instruct patients who
are overtly hypothyroid not to drive. Consider, for example,
the case of a school bus driver with severe hypothyroidism
who caused a fatal collision, cited by Rosenthal (3). First and
foremost this tragedy could have been prevented by not
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allowing an impaired driver to perform his duties. It is unclear
who would be held responsible, including the physician, if
school authorities were not notified that an overtly hypothy-
roid individual would be driving a school bus. Case law
seems to indicate that physicians who fail to warn their hy-
pothyroid patients against driving are negligent. Also, that
physicians who fail to warn third parties about an impaired
hypothyroid patient’s driving, that places the public in peril,
may be negligent (3). Anticipating how well a euthyroid pa-
tient will drive when he or she is rendered overtly hypothy-
roid is not possible. Additionally, assessing the ability to drive
safely, when the patient is overtly hypothyroid, is neither
feasible nor objective as suggested in the section on ‘‘Post-
therapy travel.’’ We therefore recommend that patients who
are overtly hypothyroid be transported by a family member to
their appointments.
In summary, the newly published recommendations of
the American Thyroid Association regarding radiation
safety for those being treated with radioactive iodine pro-
vide clinically understandable guidance to assure the
safety of family and the general public. We trust that the
authors will address our concerns and consider incorpo-
rating or referring to our practice in future versions of these
practice recommendations.
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Response to Hennessey et al.
James C. Sisson
Dear Editor:
I, and I am sure my co-authors, appreciate the kind words of
Drs. Hennessey, Parker, and Garber and Radiation Safety
Officer Kennedy in their comments on our publication, ‘‘Ra-
diation Safety in the Treatment of Patients with Thyroid
Diseases by Radioiodine (131I): Practice Recommendations of
the American Thyroid Association’’ (1). They raised three
important concepts that deserve discussion.
Patients whose thyroid glands and tissues exhibit differing
fractional uptakes and effective half-lives of 131I will expose
other people to varying levels of radiation after radioiodine
treatments. In Table 2A-1 of our article (1), we provided ex-
amples of restriction durations for hyperthyroid patients in
whom the assumed uptake was 50% at 24 hours and the ef-
fective half-life was 5 days, but the administered activities of
131I were varied. The footnote for Table 2 states that ‘‘Examples
should be modified to meet local and specific needs.’’ Inherent
in this explication is the assumption that radiation treatment
teams will calculate radiation exposure according to the vari-
ables found in a given patient. The values for the variables that
are commonly encountered are included in Table 2A-1 and
with minor adjustments may be applied to the majority of
patients. However, for some, the variables will be skewed
from the usual. In appraisals of unusual patients, measure-
ments of effective half-lives may be difficult to accomplish in a
busy clinic, but a literature search should be helpful. For ex-
ample, although effective half-lives in patients with nodular
thyroid glands are especially difficult to assess, useful data can
be gleaned from a publication by Nielsen et al. (2). For patients
with nontoxic and toxic nodular goiters, this article reports
that effective half-lives were estimated from 24- and 96-hour
thyroid uptakes. The extremes recorded can be used to cal-
culate the maximum durations of retained activities over time
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for patients with similar disorders. Then, with measurements
of thyroid uptake and the proposed treatment in mega-
becquerel (millicuries), maximum levels of radiation exposure
to others can be reasonably determined over subsequent days.
Disposal of radioactive trash can be vexing. The concerns
are not solely for the risk of radiation exposure to others, but
also for the possibility that terrorists may be using radioac-
tivity. In our publication (1), in Table 4, Step 4, under ‘‘Outside
the Home,’’ the possibility of setting off radiation detectors at
national borders, airports, and elsewhere is addressed: radi-
ation treatment teams should issue a letter or card that ex-
plains the low levels of radioactivity involved. Although, this
action was not proposed in Table 4 for disposing radioactive
trash, it offers a reasonable solution. If the radiation treatment
team projects that the level of radiation in the trash of a patient
at a given time is unlikely to threaten others, then a letter
stating this conclusion should be given to the patient; copies
can then be provided to the company that picks up the trash
and to the disposal site.
The general status and disabilities of a patient should be
assessed before any treatment is given. Limitations in activi-
ties should be advised not only for patients with hypothy-
roidism, but also for those with hyperthyroidism, Graves’ eye
disease, stroke, dementia, etc. Whereas disabilities must
be taken into account when administering 131I, these should
have previously been confronted by physicians responsible
for overall care of the patient. Nevertheless, because of its
importance, our recommendations (1) discuss the concept
of disability. In Table 3 see: under ‘‘Consider inpatient 131I
therapy . ,’’ 2. The patient is unable to comply .; and under
‘‘Information gathering for radiation precaution planning,
travel.’’ More instruction appears in Table 4, Step 2 under ‘‘For
your travel.’’
Again, we are pleased to hear from readers of Thyroid and
to have the opportunity to discuss their perturbations. We
hope that the above information allays their concerns.
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